Automate Your Wheel Strategy on PFE
With Tiblio's Option Bot, you can configure your own wheel strategy including PFE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PFE
- Rev/Share 11.2283
- Book/Share 15.6573
- PB 1.571
- Debt/Equity 0.6967
- CurrentRatio 1.1584
- ROIC 0.1119
- MktCap 139352842755.0
- FreeCF/Share 2.1879
- PFCF 11.2038
- PE 12.9582
- Debt/Assets 0.2998
- DivYield 0.0698
- ROE 0.1196
- Rating A
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 5
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
---|---|---|---|---|---|---|---|
Initiation | PFE | Cantor Fitzgerald | -- | Neutral | -- | $24 | April 22, 2025 |
Resumed | PFE | BofA Securities | -- | Neutral | -- | $29 | Dec. 10, 2024 |
Initiation | PFE | Bernstein | -- | Market Perform | -- | $32 | Oct. 17, 2024 |
News
My Top 3 Pharma Stocks
Published: October 20, 2025 by: Seeking Alpha
Sentiment: Positive
Obesity, type 2 diabetes, and cancer continue to grow across the globe, but pharma stocks remain off the radars of many investors. Many of them consistently beat the Street's consensus estimates and offer dividend yields even higher than IT, as well as oil and gas stocks. In this article, I reveal my top 3 Big Pharma players.
Read More
Pfizer's Q3 Non-Oncology Performance: Here's What to Expect
Published: October 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer's Q3 results are set to reveal mixed trends across non-oncology drugs, with strong Eliquis and Paxlovid sales offset by weakness in Abrysvo and Xeljanz.
Read More
Novo Vs. Lilly Vs. Pfizer: Who Wins If Trump Slashes The Price Of Weight Loss Drugs?
Published: October 17, 2025 by: Benzinga
Sentiment: Negative
President Donald Trump just dropped a political bomb into one of Wall Street's hottest trades. His promise to cut the cost of Novo Nordisk A/S (NYSE:NVO) blockbuster drug Ozempic from around $1,300 to $150 isn't just about affordability—it's about shaking the foundations of the GLP-1 gold rush that's reshaped healthcare valuations from Eli Lilly And Co (NYSE:LLY) to Pfizer Inc (NYSE:PFE).
Read More
What's Behind The Slump In Pfizer Stock?
Published: October 17, 2025 by: Forbes
Sentiment: Negative
Pfizer stock (NYSE: PFE) is currently in a significant slump, marking its ninth consecutive day of decline and losing a total of −11% of its value over that period. This sustained sell-off has wiped out approximately $18 billion in market capitalization, leaving its current value at around $138 billion.
Read More
CEOs of Wells Fargo and Pfizer caution the U.S. could lose its edge to China without innovation
Published: October 15, 2025 by: CNBC
Sentiment: Negative
Wells Fargo CEO Charlie Scharf said AI is boosting productivity but will likely reduce workforce size. Pfizer CEO Albert Bourla warned China is closing the biotech and pharmaceutical patent gap rapidly and said the U.S. needs to focus on innovation.
Read More
Pharma M&A Activity Picks Up Pace: What Does It Signal for 2026?
Published: October 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Big Pharma reignites dealmaking as Pfizer, Novo Nordisk and Roche target obesity and metabolic diseases in a high-stakes 2025 M&A surge.
Read More
Top Dividend Stocks Delivering Over 5% for True Financial Freedom
Published: October 14, 2025 by: 24/7 Wall Street
Sentiment: Positive
It is possible to achieve financial freedom through stock investing. If you pick the right companies, stay invested for the long term, and reinvest the dividends, you can build a solid portfolio for retirement.
Read More
3 Sizzling Ultra-High-Yield Stocks Under $50 With Upside Potential
Published: October 14, 2025 by: 24/7 Wall Street
Sentiment: Neutral
Investors can have their higher yields and capital appreciation potential, too. But, of course, there are always added risks to consider, and when it comes to the hard-hit higher-yielders out there, the fundamentals and growth narrative have taken a turn for the worse.
Read More
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
Published: October 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Pfizer's Q3: The Catalyst For A Bullish Resurgence (Earnings Preview)
Published: October 10, 2025 by: Seeking Alpha
Sentiment: Positive
Pfizer's stock is poised for recovery, driven by recent corporate news and a three-year reprieve on drug-import tariffs from the Trump administration, strengthening the bullish case despite prior market reactions. Upcoming Q3 earnings on November 4, 2025, are expected to provide clarity on oncology progress and the impact of the Trump administration's tariff decision, potentially leading to meaningful earnings revisions. Pfizer's deal with TrumpRx, offering drug discounts and committing $70 billion in U.S. manufacturing/R&D, reduces regulatory uncertainty and should attract new investors as guidance is met.
Read More
Here's What to Expect From Pfizer's Oncology Drugs in Q3 Earnings
Published: October 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer's oncology strength, powered by Seagen's ADCs and key drugs like Xtandi and Lorbrena, is likely to be in focus ahead of Q3 earnings.
Read More
Life sciences sentiment rises as Pfizer deal eases tariff concerns
Published: October 07, 2025 by: Proactive Investors
Sentiment: Positive
Sentiment towards life sciences tools and diagnostics firms in North America is turning positive after an agreement between the Trump Administration and Pfizer Inc (NYSE:PFE, ETR:PFE) has significantly eased the uncertainty around Most Favored Nation (MFN) tariffs on pharmaceuticals and related products, Citi analysts have highlighted. Under the deal announced late last month, Pfizer agreed to lower drug prices for Medicaid, sell discounted medicines directly to Americans, make significant investments in the US, and avoid tariffs for three years.
Read More
Trump's Drug Price Cuts: Boom or Bust for These 3 Pharma Giants
Published: October 06, 2025 by: MarketBeat
Sentiment: Neutral
When investors hear that a company will lower prices on its products, their instinctive reaction is to expect a sequential decline in margins and profits, which is not entirely incorrect. However, sometimes these price decreases end up attracting new business, expanding market share, and more than making up for the lost ticket price in the top-line revenue.
Read More
My Top 5 Biotech Stocks Big Pharma Could Buy Next
Published: October 06, 2025 by: Seeking Alpha
Sentiment: Positive
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their portfolios of drugs.
Read More
Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?
Published: October 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
3 Stocks Yielding 5% and More to Buy and Hold for the Next 5 Years
Published: October 06, 2025 by: 24/7 Wall Street
Sentiment: Positive

3 High-Yield Dividend Stocks to Buy in October
Published: October 06, 2025 by: 24/7 Wall Street
Sentiment: Positive
To investors, the stock market is considered one of if not the greatest ways to build wealth.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: October 06, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Read More
Is PFE Stock a Buy After 14% Rise Post Drug Pricing Deal With Trump?
Published: October 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer surges 14% after landmark Trump deal slashing drug prices while boosting U.S. investments.
Read More
The drug price deal between Pfizer and the Trump administration was built on down-to-the-wire team negotiations, building on a relationship between CEO Albert Bourla and President Trump
Published: October 02, 2025 by: WSJ
Sentiment: Neutral
Down-to-the wire team negotiations capped a long dance between President Trump and CEO Albert Bourla.
Read More
All Cap Investing With Kirk Spano
Published: October 01, 2025 by: Seeking Alpha
Sentiment: Neutral
Kirk Spano runs Margin of Safety Investing and shares what this moment means for all cap investors. Stock picking and options strategies like covered calls and cash-secured puts to generate income and manage risk.
Read More
This 6.75%-Yielding Dividend Stock Can Gain 33%
Published: October 01, 2025 by: 24/7 Wall Street
Sentiment: Positive
Pfizer (NYSE:PFE) shares are finally starting to attract attention after gaining close to 7% in a single trading session on news that it's reached a pricing deal with the Trump administration.
Read More
Pfizer Drug-Pricing Deal: More Upside For PFE Stock?
Published: October 01, 2025 by: Forbes
Sentiment: Positive
Pfizer stock (NYSE: PFE) offers a compelling investment opportunity at its current price of around $25, supported by attractive valuations and recent policy changes that may present further upside potential.
Read More
Healthy Returns: Pfizer's new obesity bet, Metsera, releases encouraging data on lead drug
Published: September 30, 2025 by: CNBC
Sentiment: Positive
Metsera released data from mid-stage trials on its lead obesity drug candidate, while a high stakes Medicare open enrollment approaches.
Read More
3 Pharma Stocks Getting an Intraday Trump Bump
Published: September 30, 2025 by: Schaeffers Research
Sentiment: Positive
Pharmaceutical stocks are enjoying tailwinds today, after President Donald Trump announced the launch of a direct-to-consumer website dubbed "TrumpRX.
Read More
Pfizer found a way to boost its ailing stock — agree with Trump on drug pricing
Published: September 30, 2025 by: Market Watch
Sentiment: Positive
Pfizer's stock surged after CEO Albert Bourla announces an agreement with the Trump administration aimed at lowering drug prices in the U.S. and removing tariff uncertainty.
Read More
What Pfizer's lower drug price agreement may mean for the company
Published: September 30, 2025 by: CNBC Television
Sentiment: Neutral
CNBC's Angelica Peebles joins "The Exchange" to detail Pfizer's agreement with the Trump administration to voluntarily sell its medications at lower prices in the United States.
Read More
Pfizer CEO: 'The big winner of this deal clearly will be the American patient'
Published: September 30, 2025 by: CNBC Television
Sentiment: Positive
Pfizer CEO Albert Bourla, speaking in the Oval Office on Tuesday about the company's deal to lower drug prices, said the winner of the deal will "clearly will be the American patient." Bourla said the company satisfied all four of the requests President Trump outlined.
Read More
Top Stock Movers Now: Spotify, Pfizer, CoreWeave, Lamb Weston, and More
Published: September 30, 2025 by: Investopedia
Sentiment: Negative
Major U.S. equities indexes edged lower Tuesday afternoon, as a potential government shutdown loomed. The Dow, S&P 500, and Nasdaq were all slightly lower.
Read More
US drugmakers rise after Trump announces Pfizer price cuts, promises more deals
Published: September 30, 2025 by: Reuters
Sentiment: Positive
Shares of Pfizer rose about 5% after U.S. President Donald Trump said on Tuesday the drugmaker will cut the price on all of its prescription drugs sold to the Medicaid insurance program and will introduce all new prescription drugs at a "most favored nation" price.
Read More
About Pfizer Inc. (PFE)
- IPO Date 1972-06-01
- Website https://www.pfizer.com
- Industry Drug Manufacturers - General
- CEO Albert Bourla
- Employees 81000